Top

Reactions Weekly

Published in:

01-07-2022 | Azithromycin | Case report

Rituximab/vemurafenib

QT interval prolongation, skin reaction and immune reconstitution inflammatory syndrome: case report

Published in: Reactions Weekly | Issue 1/2022

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Furlan A, et al. Prompt Hematological Recovery in Response to a Combination of Pegylated Interferon alpha-2a and Rituximab in a Profoundly Immuno-Suppressed Hairy Cell Leukemia Patient with a Mycobacterial Infection at Onset: Benefits and Drawbacks of Rapid Immune Reconstitution. Hematology Reports 14: 135-142, No. 2, 13 Apr 2022. Available from: URL: https://doi.org/10.3390/hematolrep14020020

Title: Rituximab/vemurafenib
QT interval prolongation, skin reaction and immune reconstitution inflammatory syndrome: case report
Publication date: 01-07-2022
Publisher: Springer International Publishing
Keywords: Azithromycin
Rituximab
Monopenia
Rituximab
Leukemia
Published in: Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-18975-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Rituximab/vemurafenib

QT interval prolongation, skin reaction and immune reconstitution inflammatory syndrome: case report

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Lomustine/temozolomide

Baricitinib

Amoxicillin/clavulanic-acid

Teriparatide

Accuretic recall due to nitrosamine impurities

Tozinameran